Benign Prostatic Hyperplasia Market Performance Analysed by GlobalData in Its Report Available at MarketPublishers.com
21 Jan 2016 • by Natalie Aster
LONDON – As of 2014, sales of the benign prostatic hyperplasia (BPH) therapeutics products across the 7 major markets (the USA, Germany, France, Italy, Spain, the UK and Japan) stood at around USD 2 billion. The USA commands the largest share (65%) of the total BPH therapeutics sales value. The BPH therapeutics sales in the USA are anticipated to reach USD 1.15 billion through 2024; the country will continue dominating the global BPH therapeutics market.
The overall BPH therapeutics sales in the 7 major markets are predicted to register positive growth at an 8.23% through 2024, and by the end of the forecast period it will likely amount to USD 4.5 billion. Growth in the worldwide BPH therapeutics market is likely to be spurred by the launch of the novel NX-1207 direct prostatic injection, which is recognised as the first-in-class therapy for the treatment of moderate-to-severe BPH.
Insightful research report “OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024” worked out by GlobalData presents an all-encompassing analysis of the current situation in the BPH therapeutics market, examines the market dynamics as well as offers a granular forecast for the market development up to 2024. A detailed overview of the existing and emerging treatment options is included in this insightful report. Moreover, the report describes the unmet needs as well as highlights possible future opportunities of the market growth. R&D strategies along with current and future clinical trials of the benign prostatic hyperplasia (BPH) therapeutics are discussed here, too.
OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
Published: September, 2015
Price: US$ 9,495.00
Other unique research reports prepared by GlobalData are available at its page.